Aastrom says its critical limb ischemia cell therapy is safe

Ixmyelocel-T cell therapy proved safe in a mid-stage clinical trial by Aastrom BioSciences, according to data presented today at the annual meeting of the American Heart Association in Orlando, Florida.  As a result of chronic inflammation and plaque build-upn in the heart, critical limb ischemia leads to blocked bloodflow to extremities and halts the healing process in wounds. However, the therapy did not show statistical significance on the amputation-free survival measure alone. The treatment is designed to shut off the body's inflammatory response system, thereby allowing new blood vessel formation.

 

SOURCE: Reuters